Evidence map›Paper›PMID 40389700›Full record

ArticleInternational journal of hematology2025

Hematopoietic cell transplantation in pediatric EB virus-associated hemophagocytic lymphohistiocytosis.

Kenichi Sakamoto, Satoshi Miyamoto, Kohsuke Imai, Maho Sato, Katsuyoshi Koh, Takashi Koike, Masataka Ishimura, Tadashi Anan, Koji Kato, Atsushi Sato and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kenichi SakamotoDepartment of Pediatrics, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan. sakamoto-k@shinshu-u.ac.jp.ORCID http://orcid.org/0000-0003-1499-538X
Satoshi MiyamotoHereditary Disorder Working Group of the Japanese Society for Transplantation and Cellular Therapy, Nagoya, Japan.
Kohsuke ImaiHereditary Disorder Working Group of the Japanese Society for Transplantation and Cellular Therapy, Nagoya, Japan.
Maho SatoDepartment of Hematology/Oncology, Osaka Women's and Children's Hospital, Osaka, Japan.
Katsuyoshi KohDepartment of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
Takashi KoikeDepartment of Pediatrics, Tokai University School of Medicine, Ishera, Japan.
Masataka IshimuraDepartment of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Tadashi AnanDepartment of Pediatrics, Kumamoto University Hospital, Kumamoto, Japan.
Koji KatoCentral Japan Cord Blood Bank, Seto, Japan.
Atsushi SatoDepartment of Hematology and Oncology, Miyagi Children's Hospital, Sendai, Japan.
Moeko HinoDepartment of Pediatrics, School of Medicine, Chiba University, Chiba, Japan.
Kimikazu MatsumotoChildren's Cancer Center, National Center for Child Health and Development, Setagaya City, Japan.
Ken TabuchiJapanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan.
Katsutsugu UmedaHereditary Disorder Working Group of the Japanese Society for Transplantation and Cellular Therapy, Nagoya, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFew reports exist on the transplant outcomes of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH). This nationwide survey evaluated the clinical outcomes of pediatric patients with EBV-HLH who underwent allogeneic HCT.

methodsData from 32 pediatric patients with EBV-HLH who underwent their first allogeneic HCT between 2000 and 2020 were reviewed retrospectively.

resultsOf the 32 patients, 12 had a performance status of 3-4 and 8 had multiple organ dysfunction. The cumulative incidence of engraftment on day 30 was 53.1% (95% confidence interval [CI] 34.1-68.9). The 1-year overall survival (OS) rate of the entire cohort was 56.2% (37.6-71.3). Univariate analysis revealed that poor ECOG-PS at HCT and a reduced-intensity conditioning regimen were significant risk factors for OS. Furthermore, multivariate analysis revealed that only ECOG-PS was a significant risk factor for OS. Sixteen of the 32 (50.0%) patients died after HCT, and the main causes of death were HLH progression (n = 12) and infection (n = 2). Most notably, 12 of the 13 patients with primary graft failure died of HLH.

conclusionGood general condition prior to HCT, which is typically achieved through optimal disease control, is essential for stable engraftment and long-term survival following allogeneic HCT.

Indexed as

Epstein-Barr Virus InfectionsHematopoietic Stem Cell TransplantationHerpesvirus 4, HumanLymphohistiocytosis, HemophagocyticAdolescentChildChild, PreschoolFemaleHumansInfantMaleRetrospective StudiesRisk FactorsSurvival RateTransplantation ConditioningTransplantation, HomologousEpstein–Barr virusEpstein–Barr virus-associated hemophagocytic lymphohistiocytosisHematopoietic cell transplantationHemophagocytic lymphohistiocytosis

Identifiers

PMID40389700

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.